Evidence map›Paper›PMID 37621062›Full record

ArticleThe clinical respiratory journal2023

Efficacy of treatment with N-acetylcysteine inhalation for AECOPD: A propensity-score-matched cohort study.

Hengyi Chen, Hui Zhou, Chen Luo, Kaican Zong, Yingya Fu, Wen Li, Chunyan Luo, Guojuan Xue, E Jiang, Yang Duan and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The clinical respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hengyi ChenDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.ORCID https://orcid.org/0000-0003-1009-6133
Hui ZhouDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Chen LuoDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Kaican ZongDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Yingya FuDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Wen LiDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Chunyan LuoDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Guojuan XueDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
E JiangDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Yang DuanDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Tinglan LuoDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Yangzhi JiangDepartment of Pulmonary and Critical Care Medicine, the Seventh People's Hospital of Chongqing, Chongqing, China.
Seventh People's Hospital of Shanghai · CN

Funding

Social Undertakings and Livelihood Security Special Projects, the Science and Technology Bureau of Banan District, Chongqing 2021-55
6 · The paper itself

Abstract

introductionN-acetylcysteine (NAC) prevents acute exacerbations of chronic obstructive pulmonary disease (AECOPD). However, the value of NAC inhalation in the treatment of patients with AECOPD is still poorly understood. The study was conducted to evaluate the efficacy of NAC inhalation in AECOPD patients requiring hospitalization.

methodsIn this single institutional, retrospective cohort study, all patients with AECOPD requiring hospitalization between January 2021 and January 2022 were included. Patients were divided into NAC group and Non-NAC group according to whether being treated with NAC inhalation and were matched using the propensity score. The primary outcome was a composite of progression to ventilation requirement, in-hospital mortality and readmission for AECOPD within 30 days. The effect on the mean hospitalized days, blood gas indexes and the incidence rate of adverse drug events were compared between the two groups.

resultsNinety-six patients in the NAC group were matched with 96 patients in the Non-NAC group. The differences in the primary composite end point (NAC group vs Non-NAC group, 5.2% vs 16.7%; P = 0.011) were significant. The median time to discharge was shorter in the NAC group (8.3 vs. 9.1 days, P = 0.030). The NAC group presented a larger increase in partial pressure of arterial oxygen (P

conclusionNAC inhalation is associated with an improved clinical outcome. A further study should be conducted to confirm the clinical usefulness of NAC inhalation in AECOPD patients.

Indexed as

AcetylcysteinePulmonary Disease, Chronic ObstructiveCohort StudiesDisease ProgressionHumansPropensity ScoreRetrospective StudiesAcetylcysteineAECOPDclinical efficacyhospitalizationN-acetylcysteine inhalation

Identifiers

PMID37621062
PMCPMC10543066
OpenAlexW4386151290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.